Angiotensin II Type 1 Receptor Blocker Usage Prevents Oxidative Stress and Muscle Dysfunction in HIV
Fundamental & Clinical Pharmacology · 2025
DOI: 10.1111/fcp.70016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Rafael Deminice und 4 weiteren Autor:innen. Beteiligte Einrichtung: Physical Education and Sports Institute, State University of Londrina, Londrina, Brazil. Hauptthemen laut MEDLINE: Oxidative Stress, Angiotensin II Type 1 Receptor Blockers, Muscle, Skeletal, HIV Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação Araucária, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
Background
We aimed to elucidate the role of Angiotensin II type 1 receptor (AT1R) blocker usage in muscle wasting and dysfunction related to HIV. Research Design and Methods Appendicular skeletal muscle mass, higher and lower limb strength, and physical fitness were determined in people living with HIV (PWH) using AT1R blockers users ( n = 33), angiotensin‐converting enzyme (ACE) inhibitors ( n = 28), or not using antihypertensive drugs ( n = 33). Groups had similar age, sex, race, BMI, and time of HIV infection. Muscle biopsies were performed to determine the abundance of AT1R, the relative abundance of selected proteins related to proteolysis, antioxidant enzymes, and oxidative stress. Plasma angiotensin II, IL‐6, and TNF‐alpha were also determined.
Results
PWH using AT1R blocker presented higher strength, physical fitness, and muscle mass than PWH using ACE inhibitors or not using antihypertensive drugs. Although both PWH using AT1R blockers and ACE inhibitors presented reduced angiotensin II plasma levels, only PWH using AT1R blockers presented lower skeletal muscle AT1R activation, lower plasma oxidative stress markers, lower skeletal muscle oxidative stress (4‐HNE), and proteolysis markers (Atrogin‐1, Murf‐1).
Conclusion
AT1R blocker usage protects against oxidative stress and activated proteolysis, contributing to the prevention of muscle wasting and dysfunction among PWH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Physical Education and Sports Institute, State University of Londrina, Londrina, Brazil.
- Biology of Ageing Laboratory, Centre for Healthy Ageing, Centenary Institute of Cancer Medicine and Cell Biology, Royal Prince Alfred Hospital, Sidney, NSW, Australia.
- Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
- Faculty of Health, School of Sport, Exercise and Rehabilitation Sciences, University of Technology Sydney, Ultimo, NSW, Australia.
- Department of Child, Family and Population Health Nursing, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Rafael Deminice
Förderung
- Fundação Araucária
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Deminice, R., Cella, P. S., Borsari, A. L., Padilha, C. S., & de Oliveira, V. H. F. (2025). Angiotensin II Type 1 Receptor Blocker Usage Prevents Oxidative Stress and Muscle Dysfunction in HIV. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70016
Vancouver
Deminice R, Cella PS, Borsari AL, Padilha CS, de Oliveira VHF. Angiotensin II Type 1 Receptor Blocker Usage Prevents Oxidative Stress and Muscle Dysfunction in HIV. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.70016
BibTeX
@article{Deminice2025,
author = {Deminice, Rafael and Cella, Paola Sanches and Borsari, Ana Lúcia and Padilha, Camila S and de Oliveira, Vitor Hugo Fernando},
title = {Angiotensin II Type 1 Receptor Blocker Usage Prevents Oxidative Stress and Muscle Dysfunction in HIV},
journal = {Fundamental & Clinical Pharmacology},
year = {2025},
doi = {10.1111/fcp.70016}
}
EUVIMED